Cargando…

MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity

Mitogen-activated protein kinase (MAPK) kinase (MEK) is an integral component of the RAS pathway and a therapeutic target in RAS-driven cancers. Although tumor responses to MEK inhibition are rarely durable, MEK inhibitors have shown substantial activity and durable tumor regressions when combined w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yarchoan, Mark, Mohan, Aditya A., Dennison, Lauren, Vithayathil, Teena, Ruggieri, Amanda, Lesinski, Gregory B., Armstrong, Todd D., Azad, Nilofer S., Jaffee, Elizabeth M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822709/ https://www.ncbi.nlm.nih.gov/pubmed/31671149 http://dx.doi.org/10.1371/journal.pone.0224600

Ejemplares similares

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
por: Shroff, Rachna T, et al.
Publicado: (2017)

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
por: Shroff, Rachna T, et al.
Publicado: (2018)

Targeting the right regulatory T-cell population for tumor immunotherapy
por: Weiss, Vivian L., et al.
Publicado: (2012)

Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures
por: Mody, Kabir, et al.
Publicado: (2022)

Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors
por: Ahn, Daniel H., et al.
Publicado: (2015)

Role of in silico structural modeling in predicting immunogenic neoepitopes for cancer vaccine development
por: Zaidi, Neeha, et al.
Publicado: (2020)

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer
por: Yarchoan, Mark, et al.
Publicado: (2017)

The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth
por: Hanson, Kimberley, et al.
Publicado: (2017)

Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors
por: Diehl, Adam, et al.
Publicado: (2017)

Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection
por: Delitto, Daniel, et al.
Publicado: (2021)

Correction: The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth
por: Hanson, Kimberley, et al.
Publicado: (2018)

Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma
por: Ryu, Sunhyo, et al.
Publicado: (2017)

Co-Treatment with Panitumumab and Trastuzumab Augments Response to the MEK Inhibitor Trametinib in a Patient-Derived Xenograft Model of Pancreatic Cancer()
por: Lindberg, James M., et al.
Publicado: (2014)

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
por: Chan, T A, et al.
Publicado: (2019)

MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody
por: Li, Hongjian, et al.
Publicado: (2020)

Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic
por: Jia, Angela Y., et al.
Publicado: (2021)

Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways
por: Ho, Won Jin, et al.
Publicado: (2021)

Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion
por: Ferguson, Jennifer, et al.
Publicado: (2012)

MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC
por: Franklin, Derek A., et al.
Publicado: (2020)

MEK inhibition suppresses metastatic progression of KRAS‐mutated gastric cancer
por: Yamasaki, Juntaro, et al.
Publicado: (2022)

Blocking STAT3 signaling augments MEK/ERK inhibitor efficacy in esophageal squamous cell carcinoma
por: Zheng, Zhen-Yuan, et al.
Publicado: (2022)

Trafficking of High Avidity HER-2/neu-Specific T Cells into HER-2/neu-Expressing Tumors after Depletion of Effector/Memory-Like Regulatory T Cells
por: Weiss, Vivian L., et al.
Publicado: (2012)

Mek1 and Mek2 Functional Redundancy in Erythropoiesis
por: Beuret, Laurent, et al.
Publicado: (2021)

Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer
por: Awasthi, Niranjan, et al.
Publicado: (2017)

Chromosome Synapsis Alleviates Mek1-Dependent Suppression of Meiotic DNA Repair
por: Subramanian, Vijayalakshmi V., et al.
Publicado: (2016)

Netrin-1 suppresses the MEK/ERK pathway and ITGB4 in pancreatic cancer
por: An, Xi-Zhou, et al.
Publicado: (2016)

Targeted elimination of senescent Ras-transformed cells by suppression of MEK/ERK pathway
por: Kochetkova, Elena Y., et al.
Publicado: (2017)

MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression
por: Farnsworth, Dylan A., et al.
Publicado: (2022)

Targeting Tuberculosis and HIV Infection-Specific Regulatory T Cells with MEK/ERK Signaling Pathway Inhibitors
por: Lieske, Nora V., et al.
Publicado: (2015)

Solid Organ Transplantation Is Associated with an Increased Rate of Mismatch Repair Deficiency and PIK3CA Mutations in Colorectal Cancer
por: Christenson, Eric S., et al.
Publicado: (2022)

PRIMA-1(Met) suppresses colorectal cancer independent of p53 by targeting MEK
por: Lu, Tao, et al.
Publicado: (2016)

Monensin suppresses cell proliferation and invasion in ovarian cancer by enhancing MEK1 SUMOylation
por: Yao, Shujuan, et al.
Publicado: (2021)

SERPINA11 Inhibits Metastasis in Hepatocellular Carcinoma by Suppressing MEK/ERK Signaling Pathway
por: Song, Ye, et al.
Publicado: (2021)

Anlotinib Exerts Anti-Cancer Effects on KRAS-Mutated Lung Cancer Cell Through Suppressing the MEK/ERK Pathway
por: Hu, Haoyue, et al.
Publicado: (2020)

Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer
por: Hampsch, Riley A., et al.
Publicado: (2017)

El jet's mek' /
por: Romero de Nieto, Carmen
Publicado: (1986)

A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer
por: Yarchoan, Mark, et al.
Publicado: (2019)

Inhibiting MEK in MAPK pathway-activated myeloma
por: Heuck, C J, et al.
Publicado: (2016)

ERRα suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells
por: Zhou, Sheng, et al.
Publicado: (2018)

Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer
por: Wagner, Steve, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0r0n0r1600pe3rn212lrtgn1d6